Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer

Abstract This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peter Arnold, Maria Cristina Penaloza-Ramos, Lola Adedokun, Sarah Rees, Mohamed Lockhat, Lisa Spary, Alan Watkins, Vincent Gnanapragasam, Simon J. Crabb
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/77469af6cc4b4e7585b202b8548a0ce0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:77469af6cc4b4e7585b202b8548a0ce0
record_format	dspace
spelling	oai:doaj.org-article:77469af6cc4b4e7585b202b8548a0ce02021-11-14T12:18:42ZClinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer10.1038/s41598-021-01042-72045-2322https://doaj.org/article/77469af6cc4b4e7585b202b8548a0ce02021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01042-7https://doaj.org/toc/2045-2322Abstract This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000–2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments.Peter ArnoldMaria Cristina Penaloza-RamosLola AdedokunSarah ReesMohamed LockhatLisa SparyAlan WatkinsVincent GnanapragasamSimon J. CrabbNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Peter Arnold Maria Cristina Penaloza-Ramos Lola Adedokun Sarah Rees Mohamed Lockhat Lisa Spary Alan Watkins Vincent Gnanapragasam Simon J. Crabb Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
description	Abstract This study used linked, routinely-collected datasets to explore incidence, clinical characteristics and outcomes of prostate cancer (PC) patients who experience a rise in prostate-specific antigen (PSA) levels despite androgen deprivation therapy (ADT), without evidence of metastases in their patient record, termed non-metastatic castration-resistant PC (nmCRPC). Routinely collected administrative data in Wales were used to identify patients diagnosed with PC and nmCRPC from 2000–2015. Logrank tests and Cox proportional hazard models were used to compare time-to-events across subgroups defined by PSA doubling time and age. Of 38,021 patients identified with PC, 1,465 met nmCRPC criteria. PC incidence increased over the study period, while nmCRPC categorizations reduced. Median time from PC diagnosis to nmCRPC categorization was 3.07 years (95% confidence interval [CI] 2.91–3.26) and from nmCRPC categorization to metastases/death was 2.86 years (95% CI 2.67–3.09). Shorter PSA doubling time (≤ 10 months, versus > 10 months) was associated with reduced time to metastases or death (2.11 years [95% CI 1.92–2.30] versus 5.22 years [95% CI 4.87–5.51]). Age was not significantly associated with time to metastases/death. Our findings highlight key clinical characteristics and outcomes for patients with nmCRPC prior to the introduction of recently approved treatments.
format	article
author	Peter Arnold Maria Cristina Penaloza-Ramos Lola Adedokun Sarah Rees Mohamed Lockhat Lisa Spary Alan Watkins Vincent Gnanapragasam Simon J. Crabb
author_facet	Peter Arnold Maria Cristina Penaloza-Ramos Lola Adedokun Sarah Rees Mohamed Lockhat Lisa Spary Alan Watkins Vincent Gnanapragasam Simon J. Crabb
author_sort	Peter Arnold
title	Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_short	Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_full	Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_fullStr	Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_full_unstemmed	Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
title_sort	clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/77469af6cc4b4e7585b202b8548a0ce0
work_keys_str_mv	AT peterarnold clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT mariacristinapenalozaramos clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT lolaadedokun clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT sarahrees clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT mohamedlockhat clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT lisaspary clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT alanwatkins clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT vincentgnanapragasam clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer AT simonjcrabb clinicalcharacteristicsandoutcomesforpatientswithnonmetastaticcastrationresistantprostatecancer
_version_	1718429294421606400

Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer

Ejemplares similares